{"id":17074,"date":"2020-02-21T07:09:40","date_gmt":"2020-02-21T07:09:40","guid":{"rendered":"https:\/\/celonpharma.com\/?p=17074"},"modified":"2022-10-19T14:46:04","modified_gmt":"2022-10-19T14:46:04","slug":"kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/","title":{"rendered":"KICHAI"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-26368 size-large aligncenter\" src=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" alt=\"\" width=\"1024\" height=\"92\" srcset=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png 1024w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-300x27.png 300w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-768x69.png 768w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max.png 1178w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/p>\n<h2 style=\"text-align: justify;\">Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases<\/h2>\n<p><!--more--><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">Funding Agreement No.: POIR.01.02.00-00-0085\/18-00 under Measure 1.2: \u201cSectoral R&amp;D programmes\u201d<br \/>\nDate of the contract conclusion: 21\/03\/2019<\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">The aim of the project is preclinical development and clinical evaluation of the innovative PI3 delta kinase inhibitor (phosphatidylinositide 3-kinase). The proposed inhibitor will be developed in the direction of the indication for the treatment of immunological and inflammatory diseases selected during preclinical development. The PI3K kinase belongs to the lipid kinase family. The delta isoform is specific to the cells of the immune system (Ito K. et al. (2007). J Pharmacol Exp Ther). It is assumed that blocking the signal amplified by PI3K delta may have a significant immunosuppressive effect.<\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">The PI3K delta inhibitor created as a result of the works conducted within the project will be innovative in the Polish and world market in terms of its therapeutic purpose and low toxicity, as well as the observed adverse effects. The PI3K delta inhibitor available on the market has been developed especially to treat oncological diseases and its high toxicity makes it impossible to use it in the treatment of inflammatory diseases. The clinical trials on new PI3K delta inhibitors are also concentrated on oncological diseases. Only some of the substances are tested for their efficacy in the treatment of inflammatory diseases, namely Sjorgen syndrome. None of these treatments, unlike our molecule, is being developed to treat psoriasis, rheumatoid arthritis or systemic lupus erythematosus. For this reason, the development of a drug would constitute a worldwide innovation in terms of its therapeutic purpose.<\/span><\/p>\n<p><strong><span lang=\"EN-GB\">Total value of the KICHAI project:\u00a0PLN 39,824,650.00<\/span><\/strong><span lang=\"EN-GB\"><br \/>\n<strong>Total value of funding:\u00a0PLN 24,516,387.51<\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-17074","post","type-post","status-publish","format-standard","hentry","category-ue-co-financed-projects-ended"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KICHAI - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KICHAI - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-21T07:09:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T14:46:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"KICHAI\",\"datePublished\":\"2020-02-21T07:09:40+00:00\",\"dateModified\":\"2022-10-19T14:46:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"articleSection\":[\"UE - co-financed projects ended\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/\",\"name\":\"KICHAI - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"datePublished\":\"2020-02-21T07:09:40+00:00\",\"dateModified\":\"2022-10-19T14:46:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KICHAI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KICHAI - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/","og_locale":"en_US","og_type":"article","og_title":"KICHAI - Celon Pharma","og_description":"Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases","og_url":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/","og_site_name":"Celon Pharma","article_published_time":"2020-02-21T07:09:40+00:00","article_modified_time":"2022-10-19T14:46:04+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","type":"","width":"","height":""}],"author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"KICHAI","datePublished":"2020-02-21T07:09:40+00:00","dateModified":"2022-10-19T14:46:04+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/"},"wordCount":290,"image":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","articleSection":["UE - co-financed projects ended"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/","url":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/","name":"KICHAI - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","datePublished":"2020-02-21T07:09:40+00:00","dateModified":"2022-10-19T14:46:04+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/kichai-preclinical-and-clinical-development-of-the-innovative-pi3-delta-kinase-inhibitor-as-a-candidate-in-the-treatment-of-inflammatory-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"KICHAI"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=17074"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17074\/revisions"}],"predecessor-version":[{"id":26422,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17074\/revisions\/26422"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=17074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=17074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=17074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}